Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 20.02.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
20.02.24Basilea Pharmaceutica - From strength to strength579FY23 was another strong year for Basilea, marked by successive guidance beats and meaningful progress in fortifying its product pipeline. Revenues of CHF157.6m were ahead of guidance, driven by c 23%...
► Artikel lesen
20.02.24Wilmington - Focus on governance, risk and compliance388With November's purchase of Astutis, January's sale of MiExact and the proposed Healthcare business disposal, Wilmington is now firmly focused on opportunities within the large global governance, risk...
► Artikel lesen
20.02.24Pan African Resources - A happy valentine324Pan African Resources' (PAF's) H124 results were released on 14 February, with earnings (and headline earnings) within 1.5% of our forecast and normalised headline earnings within 1.2% of our forecast...
► Artikel lesen
20.02.24Dentsu Group - Return to organic growth forecast for FY24434Dentsu's FY23 net revenue was a touch above guidance at Q3, with a better-than-expected operating margin reflecting a good Q4 in Japan, further boosted by a short delay in an IT project pushed out to...
► Artikel lesen
20.02.24Recce Pharmaceuticals - Supportive advancements on the pipeline290Recce Pharmaceuticals has announced several positive developments in recent weeks relating to its therapeutic programmes, particularly for lead anti-infective candidate RECCE® 327 (R327). It entered...
► Artikel lesen
20.02.24Ultimovacs - Another ODD boosts the off-the-shelf, universal UV1419Ultimovacs has been granted Orphan Drug designation (ODD) from the European Medicines Agency (EMA) for UV1 in mesothelioma, marking another step forward for the clinical development of its lead universal...
► Artikel lesen